Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years

JAMA - Journal of the American Medical Association

Volumn 317, Issue 11, 2017, Pages 1126-1140

  Barocas, Daniel A ^a   Alvarez, Jo Ann ^a   Resnick, Matthew J ^a   Koyama, Tatsuki ^a   Hoffman, Karen E ^b   Tyson, Mark D ^a   Conwill, Ralph ^c   McCollum, Dan ^c   Cooperberg, Matthew R ^d   Goodman, Michael ^e   Greenfield, Sheldon ^f   Hamilton, Ann S ^g   Hashibe, Mia ^h   Kaplan, Sherrie H ⁱ   Paddock, Lisa E ^j   Stroup, Antoinette M ^j   Wu, Xiao Cheng ^k   Penson, David F ^a,l  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^k LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^l Veterans Administration Tennessee Valley Health Care System   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; EXPANDED PROSTATE CANCER INDEX COMPOSITE 26; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL ASSESSMENT; GENITAL SYSTEM DISEASE ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT-REPORTED OUTCOME; POPULATION RESEARCH; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; SURVIVAL ANALYSIS; SURVIVAL TIME; URINARY DYSFUNCTION; URINARY IRRITATION; URINE INCONTINENCE; ADVERSE EFFECTS; BLOOD; COMPARATIVE STUDY; DECISION MAKING; ERECTILE DYSFUNCTION; INTENSITY MODULATED RADIATION THERAPY; INTESTINAL DISEASES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; URINARY INCONTINENCE; URINATION DISORDERS; WATCHFUL WAITING;

AGED; COHORT STUDIES; DECISION MAKING; ERECTILE DYSFUNCTION; HUMANS; INTESTINAL DISEASES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME; URINARY INCONTINENCE; URINATION DISORDERS; WATCHFUL WAITING;

EID: 85016110813     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.1704     Document Type: Article

References (43)

1. Thompson I, Thrasher JB, Aus G, et al; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6): 2106-2131.
2. Makarov D, Fagerlin A, Chrouser K, et al. AUA white paper on implementation of shared decision making into urological practice. Urol Pract. 2015;3 (5):1-31.
3. Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
4. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
5. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016:375(15):1415-1424.
6. Donovan JL, Hamdy FC, Lane JA, et al; ProtecT Study Group. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425-1437.
7. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611-1620.
8. Jacobs BL, Zhang Y, Skolarus TA, et al. Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer. Urology. 2012;80 (6):1236-1242.
9. Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK. Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood). 2012;31(4): 750-759.
10. Yanamadala S, Chung BI, Hernandez-Boussard TM. Robot-assisted versus open radical prostatectomy utilization in hospitals offering robotics. Can J Urol. 2016;23(3):8279-8284.
11. Oberlin DT, Flum AS, Lai JD, Meeks JJ. The effect of minimally invasive prostatectomy on practice patterns of American urologists. Urol Oncol. 2016; 34(6):255.e1-255.e5.
12. LowranceWT, Eastham JA, Savage C, et al. Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol. 2012;187(6):2087-2092.
13. Barocas DA, Chen V, Cooperberg M, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: The CEASAR study. J Comp Eff Res. 2013;2(4):445-460.
14. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5):1245-1250.
15. Skolarus TA, Dunn RL, Sanda MG, et al; PROSTQA Consortium. Minimally important difference for the expanded prostate cancer index composite short form. Urology. 2015;85(1):101-105.
16. Resnick MJ, Barocas DA, Morgans AK, et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer. 2014;120(8):1263-1271.
17. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: Conceptual framework and item selection. Med Care. 1992;30 (6):473-483.
18. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36), II: Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247-263.
19. Jayadevappa R, Malkowicz SB, Wittink M, Wein AJ, Chhatre S. Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv Res. 2012;47(5):1902-1925.
20. Resnick MJ, Koyama T, Fan K-H, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368 (5):436-445.
21. Stier DM, Greenfield S, Lubeck DP, et al. Quantifying comorbidity in a disease-specific cohort: Adaptation of the total illness burden index to prostate cancer. Urology. 1999;54(3):424-429.
22. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17(1): 168-172.
23. Haley SM, McHorney CA, Ware JE Jr. Evaluation of the MOS SF-36 physical functioning scale (PF-10), I: Unidimensionality and reproducibility of the Rasch item scale. J Clin Epidemiol. 1994;47(6): 671-684.
24. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705-714.
25. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: Evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10(2):77-84.
26. Kaplan SH, Greenfield S, Gandek B, Rogers WH, Ware JE Jr. Characteristics of physicians with participatory decision-making styles. Ann Intern Med. 1996;124(5):497-504.
27. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162-200.
28. Johansson E, Steineck G, Holmberg L, et al; SPCG-4 Investigators. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: The Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12(9):891-899.
29. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
30. Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: Early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388(10049):1057-1066.
31. Woo SH, Kang DI, Ha YS, et al. Comprehensive analysis of sexual function outcome in prostate cancer patients after robot-assisted radical prostatectomy. J Endourol. 2014;28(2):172-177.
32. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol. 2003;169(4):1453-1457.
33. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, CatalonaWJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172(6 pt 1):2227-2231.
34. Zelefsky MJ, Poon BY, Eastham J, Vickers A, Pei X, Scardino PT. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol. 2016;118(1):85-91.
35. Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):418-430. doi: 10.1016/j.eururo.2012.05.046
36. Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):405-417. doi:10.1016/j.eururo.2012.05.045
37. Bourke L, Boorjian SA, Briganti A, et al. Survivorship and improving quality of life in men with prostate cancer. Eur Urol. 2015;68(3):374-383.
38. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358 (12):1250-1261.
39. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306(11): 1205-1214.
40. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354-360.
41. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: Results from the CaPSURE registry. Eur Urol. 2015;68(4):600-608.
42. O'Neil B, Koyama T, Alvarez J, et al. The comparative harms of open and robotic prostatectomy in population based samples. J Urol. 2016;195(2):321-329.
43. O'Neil B, Hoffman KE, Koyama T, et al. Population-based comparison of patient-reported function after 3-dimensional conformal vs contemporary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2016;96(2S):E399.